- Report
- March 2024
- 187 Pages
Global
From €3242EUR$3,374USD£2,772GBP
€3602EUR$3,749USD£3,080GBP
- Report
- May 2023
- 100 Pages
Global
From €5717EUR$5,950USD£4,888GBP
- Report
- May 2024
- 354 Pages
Global
From €5381EUR$5,600USD£4,600GBP
- Report
- February 2024
- 126 Pages
Global
From €2873EUR$2,990USD£2,456GBP
- Clinical Trials
- April 2024
- 40 Pages
Global
From €1201EUR$1,250USD£1,027GBP
- Report
- February 2021
- 342 Pages
Global
From €3603EUR$3,750USD£3,080GBP
- Report
- April 2023
- 110 Pages
Global
From €4564EUR$4,750USD£3,902GBP
- Report
- January 2022
- 108 Pages
Global
From €7206EUR$7,500USD£6,161GBP
- Report
- December 2022
- 118 Pages
Global
From €4708EUR$4,900USD£4,025GBP
- Drug Pipelines
- January 2018
- 8 Pages
Global
From €9608EUR$10,000USD£8,215GBP
- Drug Pipelines
- January 2018
- 8 Pages
Global
From €9608EUR$10,000USD£8,215GBP
- Drug Pipelines
- January 2018
- 15 Pages
Global
From €9608EUR$10,000USD£8,215GBP
- Report
- March 2021
- 130 Pages
Global
From €10564EUR$10,995USD£9,032GBP
- Report
- July 2023
- 90 Pages
Global
From €3500EUR$3,902USD£3,097GBP
The Intravenous Iron market is a segment of the Hematological Drugs market, which includes drugs used to treat anemia and other blood disorders. Intravenous Iron is a type of drug used to treat iron deficiency anemia, a condition in which the body does not have enough iron to produce healthy red blood cells. Intravenous Iron is administered directly into the bloodstream, allowing for a more rapid increase in iron levels than oral iron supplements.
Intravenous Iron is used in a variety of settings, including hospitals, clinics, and home care. It is often prescribed to patients who are unable to take oral iron supplements due to gastrointestinal issues or who require a more rapid increase in iron levels.
The Intravenous Iron market is highly competitive, with a number of companies offering products in this space. Some of the major players in the market include Vifor Pharma, Fresenius Kabi, American Regent, and B. Braun. Show Less Read more